Aktienanalyse zu Replimune Group Inc (REPL)REPLReplimune Group Inc

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Replimune Group Inc is not a good buy right now due to its current price of $10.86 being significantly below the analyst price targets, which range from $19 to $21. Additionally, the stock has a very low RSI of 21.479, indicating it is oversold, but the negative trend with a 5-day change of -19.08% raises concerns about further declines. The primary risk is the ongoing negative net income, with losses reaching -86,693,000 USD in Q1 2026, which could impact future performance.

3 analysts cover REPL: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.43.